Management Based on 18F-FDG and 68Ga-DOTATATE PET/CT Findings
| Findings on which management was based | ||||
| Management | 68Ga-DOTATATE | 18F-FDG | Both | Total |
| Active surveillance | 5 | 4 | 22 | 31 (29.8%) |
| Chemotherapy | 8 | 10 | 2 | 20 (19.2%) |
| Chemotherapy, TACE | 0 | 0 | 1 | 1 (1%) |
| Everolimus | 1 | 0 | 0 | 1 (1%) |
| Interferon | 0 | 0 | 2 | 2 (1.9%) |
| PRRT | 14 | 0 | 1 | 15 (14.4%) |
| Radiofrequency ablation | 0 | 1 | 0 | 1 (1%) |
| Somatostatin analogs | 11 | 2 | 2 | 15 (14.4%) |
| Surgery | 9 | 5 | 2 | 16 (15.4%) |
| Liver-directed therapy | 2 | 0 | 0 | 2 (1.9%) |
| Total | 50 | 22 | 32 | 104 |
TACE = transcatheter arterial chemoembolization.